News and Announcements
YPB Has Strong Expectations of $5million Pre-Tax Profit Expected 2018
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
YPB Group Ltd (ASX: YPB) has recently provided a summary of activities for the quarter ended 30 June 2017.
KEY TAKEAWAYS:
- Cash receipts lower in Q2 on prior quarter as foreshadowed
- Non-COGS costs trending lower and closing in on $6.5m annualised target
- Executive leadership change in early July already increasing operational effectiveness
YPB Executive Chairman John Houston said: “While Q2 2017 was an expectedly soft quarter financially, the data show we are on target to meet our cost-out goals. More importantly, since resuming full operational control, minor changes are quickly lifting effectiveness. We have an A Grade on-field team and with the relevant resourcing, support, counsel and focus we can and will build a thriving, profitable business by driving pipeline conversion.”
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
